ARTICLE | Management Tracks
Drachman leaving Neoleukin amid restructuring
Plus: Aspesi to lead HR at Editas and updates from Homology, GlycoMimetics and Ajax
March 10, 2023 12:47 AM UTC
CEO Jonathan Drachman is departing Neoleukin Therapeutics Inc. (NASDAQ:NLTX) as the protein therapeutics company engages SVB Securities to help it review strategic alternatives. Neoleukin is planning to reduce its workforce by 70% during 1H23.
Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Linea Aspesi as EVP and chief people officer. Aspesi was chief human resources officer at Forma Therapeutics Inc. and Saniona AB (SSE:SANION)...